

Patents Assigned to CellProtect Nordic Pharmaceuticals AB

- [Expanded NK cells](#)

Patent number: 9585914

Abstract: The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.

Type: Grant

Filed: August 20, 2015

Date of Patent: March 7, 2017

Assignee: CELLPROTECT NORDIC PHARMACEUTICALS AB

Inventors: Sirac Dilber, Evren Alici

- [Expansion of NK cells](#)

Patent number: 8877182

Abstract: A method of obtaining expanded and activated natural killer (NK) cells with the phenotype CD3⁺CD56⁺ and NK-like T cells with the phenotype CD3⁺CD56⁺ comprises providing a cell sample of peripheral blood from a tumor bearing subject; isolating cells from the blood sample and re-suspending the cells in growth medium; adding the isolated cells to a closed cell culture bag bioreactor at a concentration of about 0.5×10⁶ to about 2×10⁶/ml of growth medium; incubating and expanding the cells of step ii) with rocking motion agitation and heating until at least 50% of the expanded cell population comprises activated NK cells and NK-like T cells; and harvesting the expanded cell suspension of therapeutically active NK-cells and NK-like T cells from the bioreactor, wherein the cells exhibit an increased cytotoxicity compared to freshly isolated cells as determined by an in vitro cytotoxicity test.

Type: Grant

Filed: March 25, 2010

Date of Patent: November 4, 2014

Assignee: CellProtect Nordic Pharmaceuticals AB

Inventor: Evren Alici